Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15916754 | 0.98 | TSHR (0.75) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15916530 | 0.98 | TSHR (0.75) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL29973515 | 0.96 | TSHR (0.66) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15917114 | 0.84 | USP2 (0.51) | TSHRCYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL15914906 | 0.84 | ALDH1A1 (0.52) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL30754609 | 0.84 | USP2 (0.51) | TSHRCYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL15924957 | 0.84 | TSHR (0.51) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL3087652 | 0.84 | POLB (0.59) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL20627051 | 0.84 | POLB (0.53) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15915440 | 0.82 | TSHR (0.49) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-2951170-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | disclosed |
| EP-3286178-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-02-28 | — | — | EP | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| WO-2016170009-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-10-27 | — | — | WO | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN1B | TSHR 4071/4885CYP3A4 2632/4885CYP2C9 2158/4885 |
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | TSHR 2884/4885CYP3A4 191/4885CYP2C9 899/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | TSHR 2461/4885CYP3A4 157/4885CYP2C9 782/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | TSHR 2461/4885CYP3A4 157/4885CYP2C9 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.